Article

Survival risk heterogeneity among patients with NSCLC receiving nivolumab visualized by risk scores generated from deep learning method DeepSurv using tumor gene mutations

2026-02-22

Abstract excerpt

<h4>ABSTRACT</h4> Immunotherapy with immune checkpoint inhibitors and immunotherapy combined with chemotherapy have represented promising treatments for NSCLC patients leading to prolonged survival. However, the majority of patients with advanced NSCLC have a poor prognosis. The identification and development of biomarkers for stratifying responders and non responders to immune checkpoint inhibitors contribute to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 86206216-d7c7-593a-be3f-2170ecfe9e1a
DOI: 10.64898/2026.02.15.26346303

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Survival risk heterogeneity among patients with NSCLC receiving nivolumab visualized by risk scores generated from deep learning method DeepSurv using tumor gene mutationsDOI 10.64898/2026.02.15.26346303Read

The Role of ERBB4 Mutations in the Prognosis of Advanced Non-small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSemantic proximity Read

Integration of Clinicopathological And Genomic Features To Predict The Risk Stratification of TCGA Lung Adenocarcinoma And Lung Squamous Cell Carcinoma PatientsSemantic proximity Read

Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.Semantic proximity Read

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read

A novel immune checkpoint-based signature predicts immunotherapy benefit in "driver gene-negative" lung adenocarcinoma.Semantic proximity Read

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.Semantic proximity Read

Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.Semantic proximity Read

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint InhibitorsSemantic proximity Read

Osimertinib resistance-based immune prognostic related gene signature in EGFR mutant lung adenocarcinoma, in which PSMD11 promotes tumor progressionSemantic proximity Read

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read

Prediction of 2-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors Based on a Machine Learning AlgorithmSemantic proximity Read

DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysisSemantic proximity Read